IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
FDA approves Ziihera-based regimens for first-line HER2+ gastroesophageal cancerAug 25Regulatory decisionBeiGeneJazz Pharmaceuticals